ReviewChemMedChem2026
Aminopeptidase Inhibition in Drug-Resistant Plasmodium falciparum: Structural, Functional, and Pharmacological Rationale for Targeting PfA-M1 and PfA-M17.
Review in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malaria remains a significant global health burden, increasingly threatened by the emergence of artemisinin-resistant Plasmodium falciparum strains that compromise the efficacy of frontline combination therapies. Hemoglobin digestion constitutes a central metabolic pathway sustaining intraerythrocytic parasite growth, in which the terminal processing of hemoglobin-derived peptides and liberation of free amino acids are mediated by two zinc-dependent metalloaminopeptidases, PfA-M1 (M1 alanyl aminopeptidase) and PfA-M17 (M17 leucyl aminopeptidase). This review synthesizes current evidence supporting PfA-M17 and PfA-M1 as validated antimalarial targets, with particular emphasis on the structural biology, catalytic regulation, and cellular essentiality of PfA-M17. We discuss how the oligomerization-dependent activation of PfA-M17, governed by metal-ion-mediated quaternary assembly and a dynamic regulatory loop (L13), imposes structural constraints that may limit resistance evolution. We further evaluate selective and dual-target inhibitors, including MMV1557817 and compound 26, that demonstrate cross-species antiplasmodial efficacy with substantial fitness costs on resistant parasites. The mechanistic interplay between aminopeptidase inhibition and established antimalarial drug classes, including quinolines and artemisinins, is also examined. This review supports dual PfA-M1/PfA-M17 inhibition as a promising approach for next-generation antimalarial drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.